Get startedLog in
    Picture of Hyloris Pharmaceuticals SA logo

    HYL — Hyloris Pharmaceuticals SA Income Statement

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Hyloris Pharmaceuticals SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    R2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS    		—
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue0.1753.10.92.098.46
    Cost of Revenue
    Gross Profit0.032.990.8061.998.23
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses7.213.612.518.115.6
    Operating Profit-7.03-10.5-11.6-16-7.13
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-7.14-11.3-11.9-15.4-6.34
    Provision for Income Taxes
    Net Income After Taxes-7.15-11.6-11.9-15.4-6.34
    Net Income Before Extraordinary Items
    Net Income-7.15-11.6-11.9-15.4-6.34
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-7.14-11.6-11.9-15.4-6.34
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.313-0.448-0.438-0.549-0.227